Skip to Content

Mirvaso Approval History

FDA Approved: Yes (First approved August 23, 2013)
Brand name: Mirvaso
Generic name: brimonidine
Dosage form: Topical Gel
Company: Galderma Laboratories, L.P.
Treatment for: Rosacea

Mirvaso (brimonidine) topical gel is an alpha adrenergic agonist indicated for the topical treatment of facial erythema of rosacea.

Development History and FDA Approval Process for Mirvaso

DateArticle
Aug 26, 2013Approval Galderma Receives FDA Approval of Mirvaso for the Topical Treatment of Facial Erythema of Rosacea

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide